Clinical Trials Directory

Trials / Completed

CompletedNCT01462630

Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma

Phase II Study Evaluating the Role of Pazopanib in Angiosarcoma

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
29 (actual)
Sponsor
Fox Chase Cancer Center · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This phase II trial studies how well pazopanib hydrochloride works in treating patients with advanced angiosarcoma. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Detailed description

PRIMARY OBJECTIVES: I. To determine the progression free survival (PFS) at 3 months and response rate defined as complete response (CR) and partial response (PR) in angiosarcoma patients treated with pazopanib. SECONDARY OBJECTIVES: I. To assess overall survival of patients treated with pazopanib. II. To gather more safety data for pazopanib in this patient population. III. To explore the ability of \[F-18\] fludeoxyglucose (FDG) (positron emission tomography \[PET\])/computed tomography (CT) imaging to assess response. OUTLINE: Patients receive pazopanib hydrochloride orally (PO) once daily (QD). Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months for 2 years.

Conditions

Interventions

TypeNameDescription
DRUGpazopanib hydrochlorideGiven PO
OTHERlaboratory biomarker analysisCorrelative studies
PROCEDUREpositron emission tomographyCorrelative studies
PROCEDUREcomputed tomographyCorrelative studies
RADIATIONfludeoxyglucose F 18Correlative studies

Timeline

Start date
2011-11-03
Primary completion
2019-01-02
Completion
2021-01-12
First posted
2011-10-31
Last updated
2022-08-19
Results posted
2022-08-19

Locations

5 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT01462630. Inclusion in this directory is not an endorsement.